Related Experiment Videos
[Thrombocytopenia associated with sodium polystyrene sulfonate]
1Department of Internal Medicine, Naganuma Municipal Hospital.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|January 10, 1998
Summary
This case report details a patient who developed thrombocytopenia, a low platelet count, after taking Sodium polystyrene sulfonate (Kayexalate) for hyperkalemia. The condition resolved upon discontinuation of the medication, highlighting a potential adverse effect of Kayexalate.
Area of Science:
- Hematology
- Nephrology
- Clinical Pharmacology
Background:
- Elderly patients with diabetes mellitus, hypertension, and chronic renal failure are susceptible to electrolyte imbalances like hyperkalemia.
- Hyperkalemia management is critical in patients with impaired renal function.
Observation:
- A patient presented with worsening renal function and hyperkalemia, necessitating treatment with Sodium polystyrene sulfonate (Kayexalate).
- The patient developed progressive thrombocytopenia during Kayexalate therapy, with platelet counts dropping significantly.
- Thrombocytopenia resolved after Kayexalate was stopped and recurred upon readministration.
Findings:
- Bone marrow biopsy showed normal cellularity and megakaryocytes, ruling out other causes of thrombocytopenia.
- This is the first reported instance of Kayexalate-induced thrombocytopenia.
- The temporal relationship and recurrence suggest Kayexalate as the causative agent.
Implications:
- Clinicians should be aware of the potential for Kayexalate to cause thrombocytopenia.
- Monitoring platelet counts in patients receiving Kayexalate, especially those with renal impairment, is recommended.
- Further investigation into the mechanism of Kayexalate-induced thrombocytopenia may be warranted.